Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Sargramostim (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 05 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 12 May 2016 Status changed from not yet recruiting to recruiting.